Skip to main content
Beckman Coulter secures FDA clearance for blood cancer diagnostics
7/7/2017

Beckman Coulter has obtained clearance under the FDA's de novo pathway to market its ClearLLab Reagents. The tests facilitate the diagnosis of non-Hodgkin lymphoma, chronic and acute leukemia, myeloma and other rare blood cancers using flow cytometry.

Full Story: